Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial. (1st August 2017)

• Record Type: Journal Article
• Authors: Montagna, Emilia; Palazzo, Antonella; Maisonneuve, Patrick; Cancello, Giuseppe; Iorfida, Monica; Sciandivasci, Angela; Esposito, Angela; Cardillo, Anna; Mazza, Manuelita; Munzone, Elisabetta; Lai, Antonella; Goldhirsch, Aron; Colleoni, Marco
• Is Part Of: Cancer letters. Volume 400(2017)
• Page Start: 276
• Page End: 281
• Publication Date: 2017-08-01
• Subjects: Metronomic -- Breast cancer -- Vinorelbine; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2017.01.027
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: In a phase II study we assessed the safety and efficacy of metronomic oral chemotherapy with vinorelbine, cyclophosphamide capecitabine in patients with metastatic breast cancer, either as first-line (naïve group) or second-line or greater therapy (pre-treated group). Eligible patients had histologically or cytologically proven, hormone-receptor positive metastatic breast cancer. The primary end point was median time to progression (TTP). A total of 43 patients in the naïve group and 65 in the pre-treated group were enrolled. The median TTP was 25.1 months in the naïve group and 11.2 months in the pre-treated group. The most frequently reported grade 2 treatment-related adverse events were leukopenia and hand and foot syndrome. Metronomic combination of cyclophosphamide, capecitabine and vinorelbine showed significant activity and good tolerability in patients hormonal receptor positive, metastatic breast cancer patients. Highlights: We studied a metronomic combination of cyclophosphamide, capecitabine and vinorelbine. Metronomic therapy had good tolerability in metastatic breast cancer (MBC) patients. The treatment showed significant activity. The median time to progression was 25.1 months in patients previous un-treated for MCB.